JAK2 V617F-positive essential thrombocythemia in a patient with Klinefelter syndrome: a case report

被引:3
作者
Yhim, Ho-Young [1 ]
Kim, Hee Sun [4 ]
Sohn, Ji-Youn [1 ]
Song, Min-Ju [1 ]
Lee, Na-Ri [1 ,3 ]
Song, Eun-Kee [1 ,3 ]
Choi, Sam-Im [2 ]
Yim, Chang-Yeol [1 ,3 ]
Kwak, Jae-Yong [1 ,3 ]
机构
[1] Chonbuk Natl Univ, Sch Med, Dept Internal Med, Div Hematol Oncol, Jeonju 561712, South Korea
[2] Chonbuk Natl Univ, Sch Med, Dept Lab Med, Jeonju 561712, South Korea
[3] Chonbuk Natl Univ, Sch Med, Adv Res Canc Ctr, Jeonju 561712, South Korea
[4] Jeonbuk Sci Coll, Dept Nursing, Jeongeup 580712, South Korea
关键词
TYROSINE KINASE JAK2; CANCER INCIDENCE; MYELOID METAPLASIA; MUTATION; MEN;
D O I
10.1016/j.cancergencyto.2010.01.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Klinefelter syndrome (KS) is the most commonly diagnosed X chromosome aneuploid syndrome among males. The association between hematologic malignancies such as non-Hodgkin lymphoma and leukemia and KS has been established recently on the basis of numerous case reports and a large cohort study. The risk of chronic myeloproliferative disease (MPD) as a hematologic malignancy in KS, however, has not been evaluated to date. Moreover, to our knowledge, there is only one case report that observed MPD in a patient with KS. Even though the Janus kinase 2 (JAK2) mutation was considered the primary cause in the pathogenesis of MPD, the mutation status was not described in that report. We found JAK2 V617F mutation-positive essential thromobocythemia (ET) in a patient with KS. To the best of our knowledge, this case represents the first case report of JAK2 V617F mutation in a patient with KS. Furthermore, we also suggest the hypothesis that X chromosome aneuploidy as a "pre-JAK2" cytogenetic change may be associated with the development of clonal hematopoiesis and carcinogenesis, because of the finding of higher oncogenic potential of extra X chromosome. In this study, we present the first report of JAK2 V617F-positive ET in a patient with KS, as well as a review of the relevant literature. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:162 / 165
页数:4
相关论文
共 50 条
  • [21] Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia
    Antonioli, Elisabetta
    Carobbio, Alessandra
    Pieri, Lisa
    Pancrazzi, Alessandro
    Guglielmelli, Paola
    Delaini, Federica
    Ponziani, Vanessa
    Bartalucci, Niccolo
    Tozzi, Lorenzo
    Bosi, Alberto
    Rambaldi, Alessandro
    Barbui, Tiziano
    Vannucchi, Alessandro M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (08): : 1435 - 1438
  • [22] Clinical significance of clonality assessment in JAK2V617F-negative essential thrombocythemia
    Martinez-Aviles, Luz
    Alvarez-Larran, Alberto
    Besses, Carles
    Navarro, Gemma
    Torres, Erica
    Longaron, Raquel
    Angona, Anna
    Pedro, Carme
    Florensa, Lourdes
    Serrano, Sergi
    Bellosillo, Beatriz
    ANNALS OF HEMATOLOGY, 2012, 91 (10) : 1555 - 1562
  • [23] A case of ischemic stroke with hemorrhagic transformation associated with essential thrombocythemia and JAK-2 V617F mutation
    Yan, Ran
    Mi, Donghua
    Qiu, Xin
    Li, Zixiao
    BMC NEUROLOGY, 2022, 22 (01)
  • [24] Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study
    Cascavilla, Nicola
    De Stefano, Valerio
    Pane, Fabrizio
    Pancrazzi, Alessandro
    Iurlo, Alessandra
    Gobbi, Marco
    Palandri, Francesca
    Specchia, Giorgina
    Liberati, A. Marina
    D'Adda, Mariella
    Gaidano, Gianluca
    Fjerza, Rajmonda
    Achenbach, Heinrich
    Smith, Jonathan
    Wilde, Paul
    Vannucchi, Alessandro M.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 2687 - 2694
  • [25] The V617F JAK2 mutation and the myeloproliferative disorders
    Percy, MJ
    McMullin, MF
    HEMATOLOGICAL ONCOLOGY, 2005, 23 (3-4) : 91 - 93
  • [26] JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles
    Hekimoglu, Hilal
    Toprak, Selin Fulya
    Sozer, Selcuk
    TURKISH JOURNAL OF HEMATOLOGY, 2022, 39 (01) : 13 - 21
  • [27] Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis
    Yonal, Ipek
    Daglar-Aday, Aynur
    Akadam-Teker, Basak
    Yilmaz, Ceylan
    Nalcaci, Meliha
    Yavuz, Akif Selim
    Sargin, Fatma Deniz
    TURKISH JOURNAL OF HEMATOLOGY, 2016, 33 (02) : 94 - 101
  • [28] A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia
    Verstovsek, Srdan
    Mesa, Ruben A.
    Salama, Mohamed E.
    Li, Li
    Pitou, Celine
    Nunes, Fabio P.
    Price, Gregory L.
    Giles, Jennifer L.
    D'Souza, Deborah N.
    Walgren, Richard A.
    Prchal, Josef T.
    LEUKEMIA RESEARCH, 2017, 61 : 89 - 95
  • [29] A Rare Case of Essential Thrombocythemia with Coexisting JAK2 and MPL Driver Mutations
    Jang, Mi-Ae
    Seo, Mi Yeon
    Choi, Kyoung Jin
    Hong, Dae-Sik
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2020, 35 (23)
  • [30] Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
    Komrokji, Rami S.
    Seymour, John F.
    Roberts, Andrew W.
    Wadleigh, Martha
    To, L. Bik
    Scherber, Robyn
    Turba, Elyce
    Dorr, Andrew
    Zhu, Joy
    Wang, Lixia
    Granston, Tanya
    Campbell, Mary S.
    Mesa, Ruben A.
    BLOOD, 2015, 125 (17) : 2649 - 2655